Company Profile

IPCA LABORATORIES LTD.

NSE : IPCALABBSE : 524494ISIN CODE : INE571A01020Industry : Pharmaceuticals & DrugsHouse : Ipca Laboratories
BSE2140.35-19.85 (-0.92 % )
PREV CLOSE (Rs.) 2160.20
OPEN PRICE (Rs.) 2174.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 13117
TODAY'S LOW / HIGH (Rs.)2086.00 2191.05
52 WK LOW / HIGH (Rs.)1467 2455.55
NSE2152.25 -9.65 (-0.45 % )
PREV CLOSE(Rs.) 2161.90
OPEN PRICE (Rs.) 2166.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 2152.25 (566 )
VOLUME 124272
TODAY'S LOW / HIGH(Rs.) 2136.00 2178.95
52 WK LOW / HIGH (Rs.)1466 2460

Company News

Date Heading Details
09-Apr-2021 Ipca Laboratories informs about compliance certificate <DIV align=justify><SPAN>Ipca Laboratories has confirmed that activities in relation to both physical and electronic share transfer facility are maintained during the period October 1, 2020 to March 31, 2021 by the Company's Registrar and Share Transfer Agent, Link Intime India, which is registered as Registrar &amp; Share Transfer Agent in Category-I with the Securities and Exchange Board of India vide Registration Number: INR000004058.</DIV><SPAN><DIV align=justify><BR></DIV><DIV align=justify><SPAN>The above information is a part of company's filings submitted to BSE.</DIV><DIV><BR></DIV>
02-Mar-2021 Goldman Sachs Is Hosting The Company Under<BR> Its Annual India Pharma And Healthcare Tour 2021 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Goldman Sachs is hosting the Company under its annual India Pharma and Healthcare Tour 2021 to a select set of global Investors comprising some of the largest sovereign funds, pension funds, large institutional investors, both foreign and domestic, to interact virtually with the Company''s management on Thursday, 4th March, 2021 between 10.30 a.m. to 11.30 a.m. Please note that in this virtual meeting, only publicly available information will be shared with the institutional investors. This is for your information/record.
30-Nov-2020 Ipca Laboratories informs about disclosure <DIV align=justify><SPAN>Ipca Laboratories has informed that it has enclosed disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.</DIV><SPAN><DIV align=justify><BR></DIV><DIV align=justify><SPAN>The above information is a part of company's filings submitted to BSE.</DIV><DIV><BR></DIV>
27-Oct-2020 Ipca Laboratories to hold board meeting <p align="justify">Ipca Laboratories has informed that the meeting of the Board of Directors of the Company is scheduled on 07/11/2020, to consider and take on record the Unaudited Financial Results for the 2nd quarter and half year ended 30th September, 2020 of the financial year 2020-21; and to consider declaration of Interim Dividend for the financial year 2020-21. </p><p align="justify">The above information is a part of company's filings submitted to BSE.</p>
18-Sep-2020 Ipca Laboratories informs about proceedings of 70th AGM <p align="justify">Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ipca Laboratories has informed that it has enclosed the proceedings at the 70th Annual General Meeting (AGM) of the Company held on 17th September, 2020.</p><p align="justify">The above information is a part of company's filings submitted to BSE.<br></p>
18-Sep-2020 Ipca Laboratories informs about voting results of 70th AGM <p align="justify">Pursuant to Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ipca Laboratories has informed that it has enclosed the results of the voting on the proposed resolutions along with the Consolidated Report on the voting issued by Jigyasa N. Ved of Parikh &amp; Associates, Practising company Secretaries, Scrutinizer appointed for the 70th Annual General Meeting (AGM) of the Company held on 17th September, 2020. In this regard, note that all the five (5) resolutions placed before the shareholders as per the notice of the Annual General Meeting have been passed by requisite majority.</p><p align="justify">The above information is a part of company's filings submitted to BSE.<br></p>
17-Aug-2020 Ipca Laboratories in process of obtaining environmental clearance for new plant in MP <p align="justify">Ipca Laboratories is in the process of obtaining environmental clearance for setting up a new active pharmaceutical ingredients (API) manufacturing unit at Dewas, Madhya Pradesh (MP)&nbsp;with an initial capital outlay of about Rs 250 crore. The company has already acquired land for the project. Currently, it produces over 80 APIs at 12 production facilities, accounting for nearly 25 percent of its turnover.</p><p align="justify">Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company's income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.<br></p>
05-Aug-2020 Ipca Laboratories informs about conference call <p align="justify">In accordance with Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ipca Laboratories has informed that a Conference Call to discuss the Company's Q1 FY21 earnings and business update will be held on Tuesday, 11th August, 2020 at 11.00 hrs IST.<p align="justify">The above information is a part of company's filings submitted to BSE.</p>
02-Jul-2020 Ipca Laboratories informs about company updates <p align="justify">Further to it letters dated 21st March, 2020 and 24th June, 2020, Ipca Laboratories has informed that the US FDA through its e-mail dated 1st July, 2020 has intimated the Company that the shortage implications for Hydroxychloroquine Sulphate has changed and that it has been removed from list of drug products in shortage and therefore, the US FDA is removing the exemption given to us from the import alert for API and formulation of Hydroxychloroquine Sulphate.</p><p align="justify">The above information is a part of company's filings submitted to BSE.&nbsp;</p>
24-Jun-2020 Ipca Laboratories informs about update on USFDA <p align="justify">In furtherance to letter dated 21st March, 2020 intimating USFDA exemption from import alert for APls Chloroquine Phosphate and Hydroxycholoroquine Sulfate manufactured from Company's APls manufacturing facility situated at Ratlam (M.P), Ipca Laboratories has now informed that the USFDA vide its email dated 23rd June 2020 has communicated to the Company that shortage implications for Chloroquine Phosphate API has changed and Chloroquine Phosphate drug product is&nbsp; no&nbsp; longer in shortage and therefore, no shipment of API Chloroquine Phosphate will be excluded from the import alert. USFDA has also informed hat due to potential shortage implications and/ or medical necessity, exception to the import alert has been made for API Hydroxychloroquine Sulfate. USFDA has further informed that this exception will be re-considered if the shortage implications change.<p align="justify">The above information is a part of company's filings submitted to BSE.</p>